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Objectives
Treatment with cyclical intravenous pamidronate (IVP)
improves clinical course in children with chronic recur-
rent multifocal osteomyelitis (CRMO), but theoretically
might affect longitudinal growth. In this study we ana-
lyzed growth during IVP treatment in ten CRMO patients.
Methods
10 patients (5 M, 5 F) were enrolled, with mean (range)
age 11.4 (4.5–16.3) years at IVP treatment. All patients
received a 3-day infusion of IVP (0.5 mg/kg/day for the
first dose; 1 mg/kg/day subsequently), followed by 1-day
infusion monthly or 3-day infusion every 3 months until
resolution of MRI documented bone inflammation.
Weight and height were measured prior to first IVP, at 1-
year, and at final follow-up, and results were transformed
into age- and gender-matched z-scores. Hotelling's test on
the bivariate height and weight differences between 2 time
points was performed.
Results
Patients received a mean (range) 6.23 (2.5–11.5) mg/kg/
year of IVP to achieve resolution of MRI documented
inflammation. Follow-up was a mean (range) 27.4 (16–
46) months. At baseline, 4/10 children had low baseline
height z-scores (z < -1.0), compared to 1/10 at final fol-
low-up. At one year, height and weight z-scores jointly
had increased significantly (p = 0.014). Univariate point
estimates and 95% confidence intervals (95% CI) for
average differences post-pre were height = 0.192, (95%
CI-0.16, 0.54), and weight = 0.574, (95% CI 0.10, 1.04).
Conclusion
At 1-year following first pamidronate treatment, age-and
gender-specific height and weight z-scores remained sim-
ilar or increased, suggesting that 1. Pamidronate in pedi-
atric CRMO does not have a detrimental effect on
longitudinal growth
"Catch-up growth" can occur in this selected population.
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